Mallinckrodt licenses Metasyn MRI agent
MRI contrast-agent developer Metasyn of Cambridge, MA, has landeda product development and licensing deal with Mallinckrodt Medicalof St. Louis for Metasyn's MS-325 gadolinium-based agent for MRangiography of coronary and peripheral arteries. The deal
MRI contrast-agent developer Metasyn of Cambridge, MA, has landeda product development and licensing deal with Mallinckrodt Medicalof St. Louis for Metasyn's MS-325 gadolinium-based agent for MRangiography of coronary and peripheral arteries. The deal alsoincludes other MRI vascular agents that may be developed by thecompanies.
Metasyn is beginning phase I clinical trials for MS-325, whichit hopes will replace other modalities, such as x-ray angiography,in cardiac assessment studies (SCAN 7/31/96). Mallinckrodt willmake an up-front $6 million licensing fee as part of the deal.
Mallinckrodt gains sales and marketing rights for MS-325 inall parts of the world except Japan. Metasyn granted licensingrights in that nation to Daiichi Pharmaceutical in April.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
